Basic and Clinical Research Progress of Immunotherapy for Hepatocellular Carcinoma
10.3971/j.issn.1000-8578.2023.22.1202
- VernacularTitle:肝细胞肝癌的免疫治疗基础和临床研究进展
- Author:
Zechuan ZHANG
1
;
Beicheng SUN
Author Information
1. Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China
- Publication Type:Research Article
- Keywords:
Primary liver cancer;
Hepatocellular carcinoma;
Immunotherapy;
Systemic therapy
- From:
Cancer Research on Prevention and Treatment
2023;50(4):345-400
- CountryChina
- Language:Chinese
-
Abstract:
Primary liver cancer, especially hepatocellular carcinoma, poses a serious threat to the life and health of the Chinese people. Given the insidious onset of liver cancer, less than 30% of hepatocellular carcinoma patients are considered for radical treatment at the initial diagnosis. Systemic anti-tumor therapy plays an important role in the treatment of advanced hepatocellular carcinoma. Immunotherapy of hepatocellular carcinoma has developed rapidly, and an increasing number of immunotherapy drugs, which can better control the progress of hepatocellular carcinoma and prolong the survival of patients, have become first- and second-line treatment options. This article reviews briefly the progress of immunotherapy for hepatocellular carcinoma in recent years.
